Core Viewpoint - The Hong Kong technology ETF (513020) has experienced a decline of over 1%, with market focus on performance drivers and opportunities within the AI industry chain [1] Group 1: Industry Insights - The technology sector is identified as a core theme in the "new and old coexistence" structure for 2026, following the principle of "AI technology moving downstream" [1] - Investment is shifting from core industries with strong fundamentals to downstream sectors such as commercial aerospace and AI applications, indicating a broader investment circle [1] - The AI industry chain, particularly in electronics and communication equipment, is showing significant performance releases, marking it as a key prosperity line [1] Group 2: Investment Performance - The Hong Kong Technology ETF tracks the Hong Kong Stock Connect Technology Index (931573), which encompasses core assets in "Internet + Semiconductors + Innovative Pharmaceuticals + New Energy Vehicles," reflecting a diversified technology industry characteristic [1] - From the base date at the end of 2014 to the end of 2025, the Hong Kong Stock Connect Technology Index has achieved a cumulative return of 224.25%, significantly outperforming the Hang Seng Technology Index, which recorded 83.87%, by over 140% [2] - The Hong Kong Stock Connect Technology Index has consistently outperformed similar indices, including the Hang Seng Internet Technology Index and the Hang Seng Healthcare Index [2]

Core Viewpoint - MCP concept stocks showed strong performance, with notable increases in various companies following the launch of MCP's first UI extension, "MCPApps," which enhances AI tool integration into interactive interfaces [1] Group 1: MCP Applications and Market Impact - The launch of "MCPApps" allows AI tools to embed dashboards, forms, and charts directly into conversations, moving beyond text-only interactions to a more visual and operational multi-modal workflow [1] - According to Zhongyin Securities, the expansion of MCP application scenarios is expected to improve the development efficiency of AI agents and accelerate their commercialization [1] - The "plug-and-play" feature of MCP is anticipated to significantly enhance the development efficiency of AI agents, facilitating faster commercialization [1] Group 2: Market Performance and Index Characteristics - The ChiNext 50 ETF (159367) rose by 0.74%, with significant gains in stocks such as BlueFocus (+17%), Kunlun Wanwei (+10%), and Wangsu Science & Technology (+9%) [1] - The ChiNext 50 Index focuses on sectors like information technology, new energy, fintech, and pharmaceuticals, primarily consisting of leading technology companies in fields such as optical modules, chips, new energy batteries, and innovative drugs [1] - These sectors align with national policy directions and global technological development trends, showcasing high growth potential and innovation, which are core competitive advantages of the ChiNext 50 Index [1] Group 3: ETF Advantages - The ChiNext 50 ETF (159367) has two main advantages: a 20% price fluctuation limit, providing stronger trading flexibility compared to traditional broad-based indices, and low management fees of 0.15% and custody fees of 0.05%, which effectively reduce investment costs [1]

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...

Core Viewpoint - The Hang Seng Index has reached its highest level since 2021, with both the Hang Seng Index and the Hang Seng Tech Index rising over 2.5% on Wednesday, surpassing 27,800 points [1] Group 1: Market Performance - The Hang Seng Index has achieved a new high since 2021, indicating a strong market performance [1] - Year-to-date, the A-share market, represented by the CSI 300, has remained relatively flat, while the Shanghai Composite Index has been consolidating since mid-month [1] - The Hong Kong stock market has shown a "slow bull" pattern with balanced growth in both new and old economies, driven by the resonance of domestic and foreign capital and the recovery of earnings valuations [1] Group 2: Future Outlook - Looking ahead, the first quarter may see continued space for the Hong Kong stock market due to the resonance of liquidity, capital, and earnings [1] - It is recommended to adopt an investment mindset rather than a speculative one when considering opportunities in the Hong Kong stock market [1] - The period from the Spring Festival to March could be a critical time for assessing the annual potential and style shifts in the Hong Kong stock market [1] Group 3: Investment Recommendations - Short-term focus should be on quality leaders in AI chains, specialty consumption, and innovative pharmaceuticals [1] - Mid-term recommendations include overweighting resource products, insurance, and local Hong Kong stocks [1]

2026年1月以来，公募基金调研活动持续升温，科技成长板块成为核心布局方向，AI应用、商业航天、 创新药及半导体等领域的上市公司获得重点关注。其中，大金重工、翔宇医疗、海天瑞声、爱朋医疗、 熵基科技、美好医疗、博拓生物、天承科技、三七互娱、航天宏图等多家企业均获超百家机构调研。多 位基金经理密集调研细分赛道龙头企业，聚焦技术壁垒高、场景落地明确的优质标的，清晰反映出机构 对科技领域"技术突破+业绩兑现"的双重重视。 ...

本报记者 昌校宇 2026年以来，港股市场再度成为公募机构的重点布局方向。中国证监会官网公布的信息显示，截至1月28日，年内已有27 只港股主题基金密集上报，科技、医药、周期三大赛道成为布局焦点。与此同时，资金正借道ETF持续南下，其中，富国中证 港股通互联网ETF份额突破1000亿份，成为首只跻身"千亿俱乐部"的港股主题ETF。 在资源品价格上涨的周期背景下，港股周期板块也进入公募机构的"掘金"视野。永赢基金申报的港股通周期慧选混合基 金、汇添富基金上报的港股通周期精选混合基金等，将目光投向有色金属、能源等传统周期行业。 新基金密集申报的背后，是资金持续流入港股市场的趋势性力量。今年以来，港股主题ETF持续获得资金净流入，并催生 出规模增长迅速的产品。Wind资讯数据显示，截至1月28日，富国中证港股通互联网ETF最新规模达到910.07亿元，最新份额为 1001.51亿份，成为首只份额超千亿的港股主题ETF。 兴银基金指数与量化投资部负责人、基金经理林学晨对《证券日报》记者表示："展望2026年，港股市场在估值低位、资 金持续流入以及科技股与全球产业链深度绑定的综合优势下，有望迎来估值修复与盈利增长的双轮 ...

Group 1 - The core viewpoint of the article highlights a recovery in industry demand and a clear trend of structural upgrades within the innovative pharmaceutical sector, suggesting potential investment opportunities despite a recent decline in the ETF [1] - The ETF tracking the innovative pharmaceutical index has seen a net inflow of nearly 500 million yuan over the past 10 days, indicating strong investor interest [1] - The report emphasizes the strong performance expectations for WuXi AppTec and similar companies, showcasing the growth momentum in the CXO sector, which is expected to continue benefiting from a recovering investment climate in the innovative drug industry [1] Group 2 - The article notes that the innovative pharmaceutical ETF (GTJA, 589720) tracks the innovative drug index (950161), which includes listed companies engaged in drug research and development, covering various fields such as biopharmaceuticals, chemical drugs, and traditional Chinese medicine [1] - The investment focus should shift towards the clinical value of pharmaceuticals, addressing clinical needs of patients, which is expected to command a higher premium in both domestic and global markets [1] - The report expresses optimism for the innovative drug supply chain and innovative medical devices, particularly high-end medical equipment and high-value consumables, as part of the ongoing structural upgrades in the industry [1]

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their products, with significant business development (BD) transactions announced[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% increase year-on-year, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise, with a projected increase of 33-38% for NAND Flash products due to supply constraints[36] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - The goal is to achieve a 30% share of renewable energy in total power generation by 2030, indicating significant growth potential for the solar and wind energy sectors[46]

东吴证券指出，产业层面，AI应用预计将加速落地，半导体行业开启全面涨价潮。南向资金净流入行 业主题包括TMT、科技制造，港股通净流入资讯科技业。如果市场出现回调，港股整体配置维持哑铃 策略，动态关注市场进攻方向，即AI科技。全球AI科技龙头财报在即，如果美股AI科技回调，港股AI 科技股也会受到影响。展望认为，港股仍在震荡向上的大趋势中，但短期市场仍面临考验。 港股通科技指数相比恒生科技指数超配新能源车、创新药等行业，从业绩表现来看，从2014年底基日开 始至2025年底，港股通科技指数累计收益224.25%，相对恒生科技指数（83.87%）超额超140%，长期跑 赢恒生科技指数、沪港深互联网指数、恒生互联网科技业指数、恒生医疗保健指数等同类指数。 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供参 考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构成 投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产品 要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 港股科技ETF（ ...

Group 1 - The core viewpoint indicates that AI applications are expected to accelerate in implementation, leading to a comprehensive price increase in the semiconductor industry [1] - Southbound capital inflows are focused on themes such as TMT (Technology, Media, and Telecommunications) and technology manufacturing, with net inflows into the information technology sector via the Hong Kong Stock Connect [1] - The Hong Kong stock market is anticipated to maintain a "barbell strategy" in overall allocation, dynamically focusing on AI technology as the market may face short-term tests despite a general upward trend [1] Group 2 - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), which encompasses core assets in sectors like Internet, innovative pharmaceuticals, and new energy vehicles, reflecting the diversified characteristics of the technology industry [1] - The Hong Kong Stock Connect Technology Index has outperformed the Hang Seng Technology Index, with a cumulative return of 224.25% from the base date at the end of 2014 to the end of 2025, exceeding the Hang Seng Technology Index's return of 83.87% by over 140% [1]